Moellering R C, Craig William, Edmond Michael, Farrell David J, Ferraro Mary Jane, File Thomas M, Klein Jerome, Lonks John, Metlay Joshua P, Sahm Daniel, Talbot George H
Beth Israel Deaconess Medical Center, Department of Medicine, Boston, MA 02215, USA.
J Chemother. 2002 Jul;14 Suppl 3:42-56. doi: 10.1080/1120009x.2002.11782351.
Macrolide resistance among Streptococcus pneumoniae is a growing global concern, although its specific impact on public health is not currently well defined. A Consensus Working Group was convened in March 2001 to address whether credible, scientific data substantiate macrolide resistance in S. pneumoniae as: (i) producing significant morbidity; (ii) creating attendant health and economic burdens; (iii) constituting a public health threat; and (iv) warranting intervention, including development of new antibiotics with efficacy against these strains. Despite the limitations of available clinical data, concern about the possibility of treatment failure with macrolides is being expressed in clinical practice and in formal treatment guidelines, threatening the important role of these agents in the treatment of respiratory tract infections. Further studies are required to monitor and control macrolide resistance and evaluate settings in which macrolide treatment failures are occurring, and new therapeutic interventions are needed.
